3,174
Views
0
CrossRef citations to date
0
Altmetric
Clinical Trial Protocol

HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, & ORCID Icon show all
Pages 969-980 | Received 13 Jul 2023, Accepted 23 Oct 2023, Published online: 14 Dec 2023